No abstract available
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects*
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Docetaxel / administration & dosage
-
Docetaxel / adverse effects
-
Epirubicin / administration & dosage
-
Epirubicin / adverse effects
-
Female
-
Humans
-
Ovary / drug effects*
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Primary Ovarian Insufficiency / chemically induced*
-
Primary Ovarian Insufficiency / pathology
-
Randomized Controlled Trials as Topic
-
Treatment Outcome
-
Triple Negative Breast Neoplasms / drug therapy*
Substances
-
Antineoplastic Agents
-
Docetaxel
-
Epirubicin
-
Cyclophosphamide
-
Carboplatin
-
Paclitaxel